Reports Q3 revenue $240k, consensus $1.98M. “Our third quarter demonstrated exceptional execution across our clinical portfolio,” said Marianne De Backer, Chief Executive Officer, Vir Biotechnology (VIR). “We completed ECLIPSE 1 enrollment approximately two months ahead of schedule and continue to see strong momentum across ECLIPSE 2 and 3, positioning us well for our hepatitis delta regulatory submissions. We are excited to provide guidance for a comprehensive VIR-5500 data update in the first quarter of 2026, and we recently expanded into first-line prostate cancer with our ARPI combination study. These achievements reflect our team’s commitment to delivering transformative therapies to patients with significant unmet medical needs.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology completes enrollment in ECLIPSE 1 trial
- Vir Biotechnology’s Innovative HDV Study: A Potential Game-Changer in Viral Treatment
- Vir Biotechnology’s Promising Phase 3 Study for Chronic HDV Treatment
- Vir Biotechnology’s Phase 3 Study on HDV Treatment: A Potential Game-Changer?
- Vir Biotechnology’s Innovative Approach in HER2-Expressing Cancer Treatment: A Study Update